PCOS Is Now PMOS: What the Name Change Means

On 12 May 2026, The Lancet published a consensus paper titled "Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome." It formally renamed the condition to Polyendocrine Metabolic Ovarian Syndrome, or PMOS. The paper opens by stating that PMOS, previously named polycystic ovary syndrome, affects one in eight women. This was not a small academic exercise. The process was run with 56 leading academic, clinical and patient organisations, and drew on iterative global surveys answered by 14,360 people with the condition and multidisciplinary health professionals from every world region, using modified Delphi methods and nominal group technique workshops. Notably, the group explicitly considered keeping the familiar "PCOS" acronym and decided against it. As the paper puts it, an accurate new name was prioritised over retaining the PCOS acronym or a generic name.

The problem with "polycystic ovary syndrome" is that two of the three words are misleading. The cysts are not cysts. What shows up on an ultrasound in this condition are immature follicles — egg-containing sacs that started to develop and then stalled because ovulation did not complete. They are a normal ovarian structure caught mid-process, not pathological growths. Many women have been frightened by the word "cysts" for years over something that was never a cyst. The ovaries are not the whole story. Naming a condition after an ovarian appearance directs attention to the ovaries. But the ovarian changes are downstream. The upstream drivers are insulin resistance and androgen excess — a metabolic and endocrine problem that happens to produce an ovarian finding. The Lancet consensus is direct about the consequences. It states that the term PCOS is inaccurate, implying pathological ovarian cysts, obscuring diverse endocrine and metabolic features, and contributing to delayed diagnosis, fragmented care, and stigma, while curtailing research and policy framing. That phrase — delayed diagnosis, fragmented care, and stigma — describes what a great many women have actually experienced. Being sent to a gynaecologist for what is substantially a metabolic condition. Being told to lose weight without anyone measuring insulin. Being managed as a fertility problem when the cardiometabolic risk went unaddressed.

Each word in Polyendocrine Metabolic Ovarian Syndrome is doing work. Polyendocrine — multiple hormone systems are involved, not one. Ovarian androgens, insulin, luteinising hormone, sex hormone binding globulin and adrenal androgens all interact. Metabolic — insulin resistance sits at the centre for most people with the condition. This is the piece the old name hid completely, and it is the piece that carries the long-term cardiovascular and type 2 diabetes risk. Ovarian — the ovaries are genuinely affected, with disrupted follicle development and irregular or absent ovulation. This stays in the name, but as one component rather than the headline. The consensus paper describes these as the preferred terms — polyendocrine, metabolic, and ovarian — reflecting the condition's multisystem pathophysiology. For anyone who has been told their condition is "just a fertility thing" or "just a period problem", the new name is a useful piece of evidence that it is neither.

This is the part that matters most day to day, and it is where confusion is likely. Your diagnosis is unchanged. If you were diagnosed with PCOS, you have PMOS. Same condition, same body, same diagnostic criteria. You do not need to be re-diagnosed or re-tested because of a name change. Your treatment is unchanged. Nothing about how the condition is managed changed on the day the name did. Insulin sensitivity work, inositol, nutrition, resistance training, ovulation support and any medication you take all remain exactly as appropriate as they were. The medical system still says PCOS. This is important and practical. As of now: • ICD diagnostic and billing codes still use polycystic ovary syndrome • The WHO fact sheet still uses PCOS • Most clinical guidelines still use PCOS • Your existing medical records say PCOS • Most doctors will say PCOS for some time yet The consensus paper anticipated exactly this, describing a co-designed global implementation strategy including a transition period, education, and alignment with health systems and disease classification. It also notes that implementation approaches prioritised evolution rather than transformation — a deliberate, gradual handover rather than a hard switch. So: do not walk into an appointment expecting your clinician to use PMOS, and do not worry if your chart, prescriptions or insurance paperwork still say PCOS. Both names refer to the same thing.

A name change does not treat anyone. But this one reinforces a clinical point worth acting on. If the condition is fundamentally polyendocrine and metabolic, then a workup that only looks at the ovaries is incomplete. In practice that means the assessment should include: • Fasting insulin and glucose, with HOMA-IR calculated — not glucose and HbA1c alone, which stay normal for years while insulin runs high • A full androgen panel including total and free testosterone, DHEA-S and sex hormone binding globulin • Thyroid function and prolactin, because thyroid disease and elevated prolactin mimic this condition and are treated completely differently • Lipids, vitamin D and ferritin And it means treatment should address the metabolic driver rather than each downstream symptom in isolation. Improving insulin sensitivity frequently improves cycles, acne and unwanted hair growth together, because it acts upstream of all three. That has been the better approach for years. The new name simply makes it harder to justify anything less.